Transitioning from static to suspension culture system for large‐scale production of xeno‐free extracellular vesicles derived from mesenchymal stromal cells

Abstract

AbstractExtracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs) have shown increasing therapeutic potential in the last years. However, large production of EV is required for therapeutic purposes. Thereby, scaling up MSC cultivation in bioreactors is essential to allow culture parameters monitoring. In this study, we reported the establishment of a scalable bioprocess to produce MSC‐EV in suspension cultures using spinner flasks and human collagen‐coated microcarriers (3D culture system). We compared the EV production in this 3D culture system with the standard static culture using T‐flasks (2D culture system). The EV produced in both systems were characterized and quantify by western blotting and nanoparticle tracking analysis. The presence of the typical protein markers CD9, CD63, and CD81 was confirmed by western blotting analyses for EV produced in both culture systems. The cell fold‐increase was 5.7‐fold for the 3D culture system and 4.6‐fold for the 2D culture system, signifying a fold‐change of 1.2 (calculated as the ratio of fold‐increase 3D to fold‐increase 2D). Furthermore, it should be noted that the total cell production in the spinner flask cultures was 4.8 times higher than that in T‐flask cultures. The total cell production in the spinner flask cultures was 5.2‐fold higher than that in T‐flask cultures. While the EV specific production (particles/cell) in T‐flask cultures (4.40 ± 1.21 × 108 particles/mL, p < 0.05) was higher compared to spinner flask cultures (2.10 ± 0.04 × 108 particles/mL, p < 0.05), the spinner flask culture system offers scalability, making it capable of producing enough MSC‐EV at a large scale for clinical applications. Therefore, we concluded that 3D culture system evaluated here serves as an efficient transitional platform that enables the scaling up of MSC‐EV production for therapeutic purposes by utilizing stirred tank bioreactors and maintaining xeno‐free conditions.